CombiGene’s preference issue, amounting to 31 million kronor, oversubscribed
The subscription period for a preference share issue in CombiGene AB (“CombiGene” or “the Company”) amounting to about MSEK 31 ended on 18 September 2018. The preference issue was subscribed to about MSEK 46, which corresponds to a subscription rate of about 148 percent. The issue will generate about MSEK 31.0 before deductions for issuing expenses. Consequently, the issue guarantees have not been utilized. Contract notes are expected to be sent today, 21 September 2018.
Read pressrelease >>
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.